



**Marion County**  
OREGON  
Health & Human Services

# ALERT

**COPY AND DISTRIBUTE TO  
PHARMACIES AND  
PROVIDERS**

To: Marion County Providers  
Fax number:

From: Marion County Communicable Disease  
Fax number: 503-566-2920

Date: **7/21/2025**

Regarding: Bicillin Shortage

Phone number for follow-up: 503-588-5621

Dear Providers,

King Pharmaceuticals LLC., a subsidiary of Pfizer, has issued a voluntary recall dated July 10, 2025, for select lots of **Bicillin® L-A** (Penicillin G benzathine injectable suspension) due to the presence of particulates identified during visual inspection. The affected lots were distributed between **December 11, 2023, and June 24, 2025**. A link to Pfizer's recall letter can be found [here](#).

To date, no adverse events have been reported. However, due to potential safety concerns, public health authorities and clinical providers are instructed to immediately review and quarantine affected inventory.

## **Expected Shortage and Prioritization Guidance**

This recall is anticipated to result in a national Bicillin® L-A shortage. Until further notice, remaining supplies should be prioritized for:

**Pregnant individuals with syphilis**

**Infants diagnosed with congenital syphilis**

Choose doxycycline for non-pregnant patients to help preserve Bicillin® L-A supplies.

**No pregnant person who needs syphilis treatment should go without Bicillin.** Pfizer will distribute available inventory in accordance with its medical request process, which requires that customers complete a [medical request form](#) to request product on a per patient basis. If you become aware of cases in which pregnant patients are not receiving Bicillin due to the shortage, please contact the OHA STD Program immediately for CDC reporting purposes.

If you have more Bicillin than you can use before it expires and you are able to share your supply with other sites within or outside your agency, please do so.

**Extencilline and Lentocilin** have received FDA temporary importation approval due to ongoing Bicillin® L-A shortages. Clinicians and pharmacies should consider these alternatives where appropriate. **Please note that the preparation and administration of Extencilline and Lentocilin, as well as the contraindications for prescribing, differ from those for Bicillin® L-A.**

To place an order for **Extencilline**, contact Direct Success at [Distribution@dsuccess.com](mailto:Distribution@dsuccess.com) or 1-877-404-3338. For additional information related to the product, please contact Provepharm, the U.S. distribution partner, at [medicalaffairs@provepharm.com](mailto:medicalaffairs@provepharm.com) or 610-601-8600. Extencilline is NOT eligible for discounted purchasing via the 340B Drug Pricing Program.

To place an order for **Lentocilin**, also not likely to be eligible for the 340B Drug Pricing Program, contact TopRx at [support@toprx.com](mailto:support@toprx.com) or 1-800-542-8677.

### **Returning Recalled Product**

If you have any of the affected lots in your inventory, please discontinue use, stop distribution and quarantine the product immediately. Promptly return the product to Sedgwick; 2670 Executive Drive, Suite A; Indianapolis, IN 46241; Attn: Event 8637. Contact Sedgwick at 800-805-3093 (Mon.-Fri. 8 a.m.-5 p.m. ET) to obtain pre-paid shipping labels to initiate the return process. All returns are requested to be completed within six months of the recall notice date. If you have further distributed the recalled product, please notify your accounts and/or additional locations which may have received the recalled product. Please conduct a sub-recall to those accounts and communicate this recall information immediately. Please request they immediately cease distribution and quarantine the affected product. Reimbursement for the returned product will be made by credit memorandum. Contact Pfizer Customer Service at 844-646-4398 or your Pfizer representative regarding product availability and questions regarding this market action.

If your organization has affected Bicillin® L-A received directly from the Oregon Health Authority (OHA), please contact Jillian Garai to discuss return of the product. Please note OHA's stock is recalled. We are attempting to procure additional product.

Thank you for your prompt attention to this matter and for your ongoing dedication to protecting Oregon communities.

